Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2020-08-03 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
前次募集资金使用情况的鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "鉴证报告" (Verification Report) related to the "前次募集资金使用情况" (previous fundraising capital usage). It is issued by a registered accounting firm and includes detailed verification of the use of funds raised in previous non-public stock issuances, with specific dates and amounts, and compliance with regulatory requirements from the China Securities Regulatory Commission. The document contains detailed financial data and audit verification related to the use of raised funds, including tables of fund usage, bank accounts, and project investment changes. This is a standalone audit/verification report focusing on the use of previously raised capital, not a full annual or interim report, nor a simple announcement. It is not a certification letter or a brief announcement but a detailed verification report. Therefore, it fits the category of an Audit Report / Information (AR). FY 2019
2020-08-03 Chinese
2020年度非公开发行A股股票募集资金使用的可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2020年度非公开发行A股股票募集资金使用的可行性分析报告," which translates to "2020 Feasibility Analysis Report on the Use of Funds Raised from Non-public Issuance of A Shares." The content discusses the plan for the use of funds raised through a non-public stock issuance, the necessity of supplementing working capital, the impact on the company's financial structure, and the business development implications. It is a detailed analysis report related to capital raising activities, specifically focusing on the use of proceeds from a private placement of shares. This fits the category of Capital/Financing Update (CAP), as it provides an update on the company's fundraising activities and capital structure changes. The document length is under 5,000 characters but contains substantive content, not just an announcement or a link to a report, so it is not a Report Publication Announcement (RPA). It is not a regulatory filing or certification letter, nor is it an annual or interim report. Therefore, the best classification is CAP with high confidence.
2020-08-03 Chinese
第四届监事会第七次会议决议的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the seventh meeting of the fourth Supervisory Board of Ruikang Pharmaceutical Group Co., Ltd. It discusses approval of a non-public issuance of A shares, including the conditions, pricing, issuance quantity, use of proceeds, lock-up period, and related party transactions. It also mentions the need for these resolutions to be submitted to the company's fourth extraordinary general meeting for approval. The document includes references to regulatory compliance with Chinese securities laws and the China Securities Regulatory Commission (CSRC). The content is focused on corporate governance decisions related to capital raising and share issuance, with detailed voting results and procedural information. It is not a financial report, earnings release, or audit report, but rather a formal announcement of board resolutions and related corporate actions. Given the nature of the content—board meeting resolutions and announcements of decisions regarding capital raising and share issuance—the most appropriate classification is Capital/Financing Update (CAP). The document length (7309 characters) and detailed content support that this is not a mere announcement of a report publication but a substantive disclosure of financing decisions.
2020-08-03 Chinese
2020年度非公开发行A股股票预案
Capital/Financing Update Classification · 100% confidence The document is titled as a "2020 A 年度非公开发行 股股票预案" which translates to "2020 Annual Non-public Issuance of A Shares Stock Proposal." The content extensively discusses the company's plan for a non-public issuance of shares, including details about the issuance price, number of shares, issuance purpose, background, approval procedures, and related parties. It includes detailed financial and corporate governance information related to the capital raising activity. There is no indication that this is a full annual report or quarterly report, nor is it an announcement of voting results or a proxy statement. The document is a detailed plan and proposal for a capital raising event through non-public issuance of shares, which fits the definition of a Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is the actual proposal, not just an announcement of a report. Therefore, the correct classification is Capital/Financing Update (CAP).
2020-08-03 Chinese
关于原持股5%以上股东减持计划实施完毕的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the completion of a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the number of shares reduced, the period, methods, prices, and compliance with relevant securities laws and exchange rules. The content focuses on changes in major shareholding levels and does not contain financial statements, management discussion, or audit information. It is a typical major shareholding notification reporting a decrease in significant ownership below the 5% threshold. Therefore, the appropriate classification is Major Shareholding Notification (MRQ). The document length is 2698 characters, consistent with a detailed announcement but not a full report.
2020-08-03 Chinese
关于前次募集资金使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the usage of previously raised funds by the company 瑞康医药集团股份有限公司 (Ruikang Pharmaceutical Group Co., Ltd.). It includes specifics about the amounts raised in non-public stock issuances in 2014 and 2015, the storage and use of these funds, changes in investment projects, and the actual investment and benefits realized from these funds. The document references regulatory requirements from the China Securities Regulatory Commission and includes detailed tables comparing committed and actual use of funds. It is a comprehensive disclosure about the use of capital raised in prior financing rounds, focusing on compliance and transparency regarding the use of proceeds. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital usage. The document is lengthy (15,000 characters) and contains substantive financial and project usage data, not merely an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2020-08-03 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.